RxDoctor Payments Data

Joseph Tolwin

Psychiatric/Mental Health · Culver City, CANPI 1952083867

Payments from drug & device makers

$3,349in general payments, 2019–2025

Across 188 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$911
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$726
  • Alkermes, Inc.$695
  • Vanda Pharmaceuticals Inc.$314
  • Indivior Inc.$208
  • Neurocrine Biosciences, Inc.$135
  • plus $359 from 5 others

What the payments were for

  • Food & beverage$3,30099%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,349 in reported general payments places this provider in the 85th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$384,333
Medicare patients
759
Services billed
5,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$203,517
Invega SustennaPaliperidone Palmitate24$89,248
Lurasidone Hcl72$67,741
VraylarCariprazine Hcl14$19,399
Aripiprazole188$11,382
RisperdalRisperidone13$10,126
Divalproex Sodium268$8,053
Olanzapine294$7,643
Quetiapine Fumarate430$7,477
Clozapine135$6,580
Chlorpromazine Hcl25$4,661
Mirtazapine282$4,459
Olanzapine OdtOlanzapine53$4,001
Buspirone Hcl247$3,077
Divalproex Sodium ErDivalproex Sodium63$3,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$135$203,51725 claims
Johnson & JohnsonInvega Sustenna, Risperdal$911$99,37537 claims
AbbVieVraylar$94$19,39914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Culver City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →